HENNEMAN JOHN B III 4

What Happened

• John B. Henneman III, a director of Anika Therapeutics, acquired 5,000 shares of ANIK in an open-market purchase on 2026-05-01. The filing reports a weighted-average price of $14.66 per share, for a total cost of approximately $73,320. This was a purchase (insider buying).

Key Details

• Transaction date: 2026-05-01; Form 4 filed: 2026-05-04 (filed within required reporting window).
• Reported price: weighted average $14.66; purchases occurred at prices ranging from $14.595 to $14.75 (footnote F1).
• Total shares acquired: 5,000; total value ≈ $73,320.
• Shares owned after the transaction: Not disclosed in this Form 4.
• Notable footnote (F1): The reported price is a weighted average; the purchaser made multiple trades across the $14.595–$14.75 range and will provide a per-price breakdown to the company, shareholders, or SEC staff on request.

Context

• Insider purchases are often watched by investors as a signal that insiders are willing to buy the company’s stock, though they do not guarantee future performance. This filing relates to a director’s open-market purchase (code P), not an option exercise, award, or gift.